S. Vigouroux

M. Robin, P. Chevallier, I. Yakoub-Agha, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

R. Porcher, H. Dombret, M. Robin, 2015, Leukemia.

Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

M. Labopin, P. Chevallier, D. Blaise, 2015, Cancer.

Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells.

P. Amrolia, E. Yvon, M. Brenner, 2003, Blood.

M. Bernard, P. Chevallier, I. Yakoub-Agha, 2016, Haematologica.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

S. Chevret, P. Chevallier, I. Yakoub-Agha, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria

D. Blaise, M. Mohty, J. Passweg, 2012, Haematologica.

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

M. Labopin, P. Chevallier, D. Blaise, 2014, Haematologica.

Romiplostim (AMG531, Nplate®) for Secondary Failure of Platelet Recovery After Allogeneic Stem-Cell Transplantation

N. Milpied, R. Tabrizi, C. Calmettes, 2011 .

Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.

M. Robin, P. Chevallier, I. Yakoub-Agha, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

M. De Carvalho Bittencourt, L. Reppel, D. Bensoussan, 2017, Journal of Hematology & Oncology.

Rapid and Sustained Engraftment of a Single Allogeneic Ex-Vivo Expanded Cord Blood Unit (CBU) After Reduced Intensity Conditioning (RIC) in Adults. Preliminary Results of a Prospective Trial

G. Marit, N. Milpied, R. Tabrizi, 2011 .

Impact of Antithymocyte Globulins on Patient Outcome after Myeloablative Bone Marrow Stem Cell Transplantation from HLA 10/10-Matched Unrelated Donor: A Report from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

I. Yakoub-Agha, M. Mohty, J. Bay, 2014 .

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy

J. Bourhis, I. Yakoub-Agha, M. Mohty, 2013, Haematologica.

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy

M. Robin, P. Chevallier, I. Yakoub-Agha, 2015, Transplantation.

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

J. Esteve, M. Labopin, I. Yakoub-Agha, 2015, Journal of Hematology & Oncology.

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

D. Blaise, M. Mohty, J. Bay, 2012, Annals of Hematology.

Induction of Antigen-Specific Regulatory T Cells following Overexpression of a Notch Ligand by Human B Lymphocytes

C. Rooney, E. Yvon, M. Brenner, 2003, Journal of Virology.

A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

H. Heslop, C. Rooney, C. Bollard, 2004, Cancer Gene Therapy.

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

J. Esteve, M. Labopin, J. Finke, 2016, Bone Marrow Transplantation.

Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.

M. Labopin, G. Marit, S. Dimicoli-Salazar, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.

G. Marit, A. Schmitt, N. Milpied, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, M. Labopin, 2015, Haematologica.

M. Beylot-Barry, N. Milpied, R. Tabrizi, 2016, Bone Marrow Transplantation.

Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial

M. Labopin, P. Chevallier, D. Blaise, 2012 .

Shaping of iNKT cell repertoire after unrelated cord blood transplantation.

P. Debré, P. Chevallier, V. Vieillard, 2010, Clinical immunology.

J. Bourhis, P. Chevallier, I. Yakoub-Agha, 2018, American journal of hematology.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

J. Bourhis, P. Chevallier, D. Blaise, 2016, Bone Marrow Transplantation.

Infections Cryptococcus neoformans dans les hmopathies malignes

B. Mahé, N. Milpied, J. Harousseau, 2000 .

Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases.

P. Moreau, C. Touzeau, J. Delaunay, 2006 .

Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD,

E. Lippert, G. Marit, F. Mahon, 2011 .

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

H. Dombret, I. Yakoub-Agha, E. Deconinck, 2017, Leukemia research.

Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.

M. Labopin, G. Marit, F. Mahon, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin

G. Marit, A. Schmitt, N. Milpied, 2012, Leukemia & lymphoma.

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

R. Porcher, M. Robin, I. Yakoub-Agha, 2013 .

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Elsa, P. Chevallier, M. Béné, 2021 .

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

P. Chevallier, M. Béné, P. Moreau, 2020, Haematologica.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC)

I. Yakoub-Agha, D. Blaise, M. Mohty, 2016, Haematologica.

Medication non‐adherence after allogeneic hematopoietic cell transplantation in adult and pediatric recipients: a cross sectional study conducted by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

J. Bourhis, I. Yakoub-Agha, J. Bay, 2020, Fundamental & clinical pharmacology.

Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia.

P. Chevallier, J. Harousseau, P. Talmant, 2008, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.

R. Porcher, G. Socié, F. Suarez, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

No adverse effect of granulocyte colony-stimulating factor during the peri-implantation period of an unrecognized pregnancy in a donor of peripheral blood stem cells

N. Milpied, S. Vigouroux, Lucile Debus, 2017, Leukemia & lymphoma.

Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT

F. Baron, M. Labopin, P. Chevallier, 2018, Journal of internal medicine.

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.

H. Heslop, C. Rooney, W. Xie, 2003, Cytotherapy.

Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.

M. Labopin, A. Nagler, M. Mohty, 2015, The Lancet. Haematology.

Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.

J. Harousseau, S. Vigouroux, NoE¨l Milpied, 2006, Haematologica.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2017, Haematologica.